For Immediate Release
Chicago, IL – October 7, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Facebook
FB
, Tesla
TSLA
, Lockheed Martin
LMT
, Starbucks
SBUX
and American Express
AXP
.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Facebook, Tesla and Lockheed Martin
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Facebook, Tesla and Lockheed Martin. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of
today’s research reports here >>>
Facebook
shares have lost some ground over the past month or so, but the stock has nevertheless been a strong performer this year (up +28.1% in the year-to-date period vs. +5.8% gain for the S&P 500 index). The Zacks analyst expects the stock’s outperformance to continue on the back of steady user growth across all regions, particularly Asia Pacific.
The coronavirus-led lockdowns and shelter-at-place guidelines have increased engagement of its products like Instagram, WhatsApp, Messenger and Facebook Watch. However, Facebook expects user-base growth to be flat or slightly down in most of its regions in the third quarter of 2020, sequentially. The company expects ad-revenue growth on a year-over-year basis to be roughly 10%.
Facebook assumes some of the recent surge in community engagement to normalize as regions reopens. Further, a number of companies have announced plans to freeze ad spending on Facebook due to its failure to eradicate hate speech and misinformation. This is expected to hurt top-line growth, at least in the near term.
(You can
read the full research report on Facebook here >>>
)
Shares of
Tesla
have gained +783.9% over the past year against the Zacks Domestic Automotive industry’s rise of +197%. The Zacks analyst believes that Tesla has a first-mover advantage in the EV space with high range vehicles, superior technology, and software edge.
Robust Model 3 demand, ramp up of Model Y production, significant Shanghai Gigafactory progress, amazing line-up of upcoming products and aggressive expansion efforts bode well for the firm. The red hot EV maker smashed forecasts and posted the fourth consecutive quarterly profit in the last quarter.
However, high R&D, SG&A costs and massive capex may clip the margins. Tesla is investing heavily to increase production capacity, boost sales and construct Gigafactories, which are likely to strain its near-term prospects. Waning margins for Model S/X is another concern. Thus, investors are recommended to wait for a better entry point.
(You can
read the full research report on Tesla here >>>
)
Lockheed Martin
shares have gained +8.3% over the past six months against the Zacks Aerospace Defense industry’s rise of +6.5%. The Zacks analyst believes that expansionary budgetary provisions made by the U.S. administration will immensely boost this defense primes business. It continues to be a strong cash generator.
Lockheed Martin enjoys strong demand for its high-end military equipment in domestic and international markets, being the world’s largest defense contractor. Lockheed Martin is further witnessing increased demand for its THAAD missiles from the Kingdom of Saudi Arabia (KSA).
However, forced cost reduction initiatives for F-35 program might hamper its operating results. America and Turkey’s tiff about the latter accepting Russian products may hurt Lockheed’s component supply from Turkey. It is facing performance issues in relation to some of its products, which in turn may hurt it results.
(You can
read the full research report on Lockheed Martin here >>>
)
Other noteworthy reports we are featuring today include Starbucks and American Express.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released
Century of Biology: 7 Biotech Stocks to Buy Right Now
to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Join us on Facbook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report